Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial
Crossref DOI link: https://doi.org/10.1186/s12876-016-0494-4
Published Online: 2016-08-02
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Burke, Carol A.
Dekker, Evelien
Samadder, N. Jewel
Stoffel, Elena
Cohen, Alfred
Funding for this research was provided by:
Cancer Prevention Pharmaceuticals, Inc.
License valid from 2016-08-02